Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Equities research analysts at Zacks Research lowered their FY2023 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, January 23rd. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.85) for […]
Nektar Therapeutics (NASDAQ:NKTR) Receives $3.00 Consensus PT from Brokerages themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Nektar Therapeutics (NASDAQ:NKTR) Receives $3.00 Consensus Price Target from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 5,350,000 shares, a decrease of 23.1% from the December 15th total of 6,960,000 shares. Based on an average trading volume of 1,560,000 shares, the short-interest ratio is […]
StockNews.com began coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently issued reports on NKTR. TD Cowen upgraded Nektar Therapeutics from a market perform rating to […]